RIVANNA's next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(k) clearance

CHARLOTTESVILLE, Va., July 16, 2025 /PRNewswire/ -- RIVANNA^®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro^® 3S diagnostic ultrasound system and SpineNav-AI^™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or catheter placement. 

Accuro 3S is a portable, point-of-care ultrasound system with a proprietary, Dual-Array^™ convex probe and integrated SpineNav-AI software. The Dual-Array probe consists of two aligned transducer arrays arranged side by side with a narrow gap, enabling an in-line needle approach through the probe's center. Images from both arrays are combined to optimize anatomical visualization. This platform supports standard B-mode imaging and is equipped with a touchscreen interface, a maneuverable cart-based form factor, and healthcare IT connectivity to implement DICOM-based patient and image archival workflows.

SpineNav-AI is a machine learning-based software solution that facilitates musculoskeletal imaging assessments of the lumbar spine to support real-time visualization during anesthesia procedures. It provides automated landmark detection and identification of critical spinal anatomy which may assist clinicians by standardizing interpretation of spinal images. The software utilizes an AI-based image processing architecture to identify key anatomical structures in ultrasound images and indicate the position of the spine midline. The position of the epidural space and the measurement of depth to the epidural space are indicated when the epidural space is detected by the SpineNav-AI software.

"Achieving 510(k) clearance for Accuro 3S and SpineNav-AI ahead of schedule marks a significant milestone for RIVANNA and demonstrates the strength of our engineering and clinical partnerships. We are excited to introduce this next-generation platform to the market and continue advancing innovation in image-guided anesthesia procedures," said Will Mauldin, PhD, RIVANNA Co-founder and CEO.

The Accuro 3S platform builds on RIVANNA's clinically validated track record of increasing first-attempt success rates in spinal procedures. The system introduces enhanced imaging capabilities and integrated software tools to further support accuracy and efficiency in neuraxial anesthesia procedures. RIVANNA has implemented consumable products for the system, including a Probe Cover Needle Guide Kit, designed to stabilize probe positioning and facilitate needle alignment. This workflow enhancement will enable the clinician to locate the epidural space, assess its depth, and insert the needle under live visualization.

This innovation tackles longstanding challenges in procedural guidance, according to Mauldin. "Historically, ultrasound-guided neuraxial procedures have been limited by the need to simultaneously handle the needle, probe, and syringe, as well as by steep needle angles that restrict visualization, and difficulty maintaining a real-time in-plane approach with conventional probes. Our solution addresses these technical barriers, making ultrasound guidance more accessible and supporting enhanced safety, precision, and patient care."

RIVANNA's next steps include pursuing additional regulatory submissions for additional advanced Accuro 3S capabilities. Clinical collaborations are underway, with a forthcoming limited release of Accuro 3S to select leading academic medical centers, followed by a broader market launch.

About RIVANNA
RIVANNA^® is a commercial-stage medical device innovator and manufacturer based in Charlottesville, VA. The company develops and commercializes world-first imaging-based medical technologies that elevate global standards of care. RIVANNA offers early- and late-stage comprehensive imaging solutions for point-of-care spinal needle interventions and musculoskeletal diagnostics. Learn more: RIVANNA.

SOURCE RIVANNA